Print Page- About BNMS
- Membership
- Events
- News
- Working in NM
- Resources
- Radionuclide Supply
- UKRG
- MRT Consortium
| Industry News |
|
Industry News
Introducing the new eco-friendly range of Helapet Sterile Sharps Bins
Helapet are pleased to announce a major development in the range of Sterile Sharps Bins. The new “Eco” range of sharps containers are made from at least 40% recycled plastic, assisting the NHS drive to reach Net Zero by 2040. The new Eco range will conform to HTM07-01 management and disposal of healthcare waste guidelines. This means they are still a standard yellow container with yellow or purple lids for cytotoxic /cytostatic waste. Due to the recycled material, the yellow will be a darker tone in contrast to the current model. The new eco range of Sterile Sharps Bins contain a minimum of 40% high grade recycled material to help minimise the impact on our environment and the carbon footprint during its manufacture. This also means there is less dependence on crude oils used in the manufacture of virgin plastic. The new Eco Sharps Bin range is fully compliant with UN 3291 and ISO 23907-1:2019 standards. Having a mainly yellow base with the appropriate coloured lid it is also in line with HTM 07-01 waste segregation guidance. They are also compatible with the same accessories, trolleys, and brackets as the current ones. The new ECO range of Sterile Sharps Bins will be phased in from June 2022. Current customers will not need to change anything to begin receiving the new bins. Just place your order the usual way using the same product codes. Reducing the amount of single use plastic is a challenge in our industry but it’s one that Helapet embraces. One of our key goals is to incorporate sustainability where possible across all areas of our business operations from facility management to work practices, delivering sustainable solutions that benefit the environment. For additional information and latest prices on any of our listed products, please email sales@helapet.co.uk or call 01582 501980 helapet.co.uk | Sign up to our mailing list for further product updates, or follow us on Twitter , LinkedIn or Facebook 23.01.2023 RadioMedix & Curium Announce Simplified Coding for DetectnetTM (copper Cu 64 dotatate injection)(St. Louis, MO – March 23, 2021) - RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has simplified the coding process for Detectnet. Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients. While Transitional Pass-Through Status remains in effect for Detectnet, the current C9068 HCPCS code will be retired April 1, 2021. For services performed prior to April 1st, C9068 should continue to be used for Medicare patients at Hospital Outpatient Department Imaging Facilities. The descriptor for Detectnet remains: Copper Cu-64, dotatate, diagnostic, 1 millicurie. "Once in effect, having one code for all patients regardless of the site of care will simplify the billing process for our customers,” said Curium Vice President of Sales, North America, Andy Farrow. “We remain focused on helping physicians and patients in the neuroendocrine community and anticipate this change to positively impact coding and billing procedures for all sites." "The response to Detectnet from the neuroendocrine community is outstanding,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “The Phase III results demonstrate the clinical sensitivity, specificity, and accuracy of Detectnet. Further, the 12.7-hour half-life of Detectnet enables it to be produced centrally and shipped to sites throughout the U.S. The single HCPCS code is another step to simplifying the insurance billing process for imaging centers nationwide." About Detectnet INDICATIONS Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. IMPORTANT RISK INFORMATION WARNINGS AND PRECAUTIONS Radiation Risk Diagnostic radiopharmaceuticals, including Detectnet, contribute to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Risk for Image Misinterpretation The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors. Increased uptake might also be seen in other non-cancerous pathologic conditions that express somatostatin receptors including thyroid disease or in subacute inflammation, or might occur as a normal physiologic variant (e.g. uncinate process of the pancreas). A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease. ADVERSE REACTIONS In clinical trials, adverse reactions occurred at a rate of < 2% and included nausea, vomiting and flushing. In published trials nausea immediately after injection was observed. DRUG INTERACTIONS Somatostatin Analogs Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2). Image patients just prior to dosing with somatostatin analogs. For patients on long-acting somatostatin analogs, a wash-out period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging. USE IN SPECIFIC POPULATIONS Pregnancy All radiopharmaceuticals, including Detectnet, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of Detectnet. Lactation Advise a lactating woman to interrupt breastfeeding for 12 hours after Detectnet administration in order to minimize radiation exposure to a breastfed infant. Pediatric use The safety and effectiveness of Detectnet have not been established in pediatric patients. Geriatric use In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. OVERDOSAGE In the event of a radiation overdose, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by reinforced hydration and frequent bladder voiding. A diuretic might also be considered. Please see Full prescribing information by clicking here. About RadioMedix RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, and probe development and small animal Molecular Imaging Facility for pre-clinical evaluation of radiopharmaceuticals in animal models. To learn more, visit www.radiomedix.com. For more information about this press release, please contact: media@radiomedix.com About Curium Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com. For more information about this press release, please contact Janet Ryan, media contact for Curium: janet@ryan-pr.com. About Neuroendocrine Tumors Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract, pancreas and liver, but can also occur in other tissues including lung, thymus and other uncommon sites such as cervix, heart and prostate. Most NETs strongly express somatostatin receptors (SSTRs). 24.03.2021 The London Clinic is UK’s first independent hospital to introduce OncoSilTM – an innovative nuclear medicine to treat pancreatic cancerThe London Clinic, a leading independent hospital and charity located in London’s Harley Street Medical Area, is the first independent hospital in the UK to employ OncoSilTM, a breakthrough new treatment for pancreatic cancer. 
OncoSilTM is a single-use brachytherapy device (internal radiation) that delivers a pre-determined dose of beta-radiation directly into cancerous tissue. It is used in combination with chemotherapy to treat patients with locally advanced pancreatic cancer. Pancreatic cancer occurs when abnormal cells in the pancreas grow out of control, with symptoms varying according to the tumour type and location. People often do not show symptoms in the earlier stages of the disease and so it is difficult to detect. Pancreatic cancer has the lowest survival rate of all common cancers, with a five-year survival rate of less than 7%.i This new nuclear medicine therapy offers a new option for the treatment of locally advanced pancreatic cancer where the tumour is unresectable – meaning it is too large or infiltrative to be operated on. The beta particles emitted by OncoSil™ cause damage to cancer cell DNA which renders them incapable of further cell division which can ultimately shrink the tumour mass. 
OncoSilTM has been shown in clinical studies to increase overall survival and lead to downstaging, allowing patients to undergo surgery to remove their tumours. This surgery statistically improves the five-year survival rate from ~7% to >20%. 
OncoSil™ implantation is an out-patient procedure which takes around 60 minutes. Dr Zarni Win, Consultant Radiologist and Nuclear Medicine Physician at The London Clinic, said: 
Nigel Lange, CEO and Managing Director, OncoSil Medical President, EMEA said: During the PanCO clinical study, which had participating sites in Australia, UK and Belgium, a total of 50 subjects were enrolled in the study with 42 subjects successfully implanted with the OncoSilTM device.ii Our clinicians performed the largest number of implantations in the UK/EU during this study. The London Clinic will be the first centre in the UK to treat patients using this technology in 2021. FOR MORE INFORMATION, MEDIA INTERVIEWS AND IMAGES, CONTACT: Notes to Editors About The London Clinic The London Clinic is the UK’s leading private charitable hospital, situated in Harley Street, the heart of London’s medical district. Opened in February 1932 by the Duke and Duchess of York (later becoming King George VI), The London Clinic has been at the forefront of healthcare for close to 90 years. Our services are provided across seven buildings housing ten theatres, 234 beds, consulting rooms and a wide range of diagnostic services, including the latest 3T MRI scanner. The Duchess of Devonshire Wing, The London Clinic’s custom-built cancer centre, spans eight floors, offering access to state-of-the-art radiotherapy and chemotherapy suites, along with Europe’s largest private stem cell collection and storage facility. We were the first independent hospital in the UK to gain the Joint Accreditation Committee ISCT Europe and EBMT (JACIE) accreditation in recognition of our quality standards in stem cell work. As a full-service hospital, The London Clinic offers the most comprehensive range of services of any UK private hospital, including a 13 bed, Level 3 Intensive Care Unit and in-house pathology laboratory. We employ over 1,300 expert nurses, allied healthcare professionals, doctors and support roles. Our 600 world-class consultants specialise in cancer care, digestive diseases, orthopaedics (including hips, knees, shoulders and fingers with on-site physiotherapy rehabilitation), neurology, cosmetic surgery, liver services, gastroenterology, urology, endoscopy, diabetes, haematology and endocrinology. As a charity, The London Clinic reinvests all profits to further our mission of advancing healthcare within our hospital and for the benefit of the healthcare community. We were the first private hospital in the UK to introduce robotic surgery for prostate cancer and SpyGlass technology for endoscopy, and are the only UK hospital supporting the phase three international clinical trial for Intra Operative Radiotherapy on glioblastoma multiforme. We continue to invest significantly in the education of our people, supporting nurses to complete their degrees and fellows to become consultants. Find out more at www.thelondonclinic.co.uk Follow us on LinkedIn and Twitter.
About OncoSil Medical At OncoSil Medical we have one mission – to transform the prognosis for people with cancer. Our first priority is pancreatic cancer. For 40 years the prognosis for this condition has remained almost unchanged. Less than 8% of patients with pancreatic cancer survive five years. The statistics have left patients and doctors little room for hope. Until now. OncoSil Medical is an innovative Australian medical technology company focused on interventional oncology. We’re passionate about improving outcomes for people with cancer. We believe it’s time to change the conversation around cancers with poor prognoses and transform the approach to their treatment. OncoSil™ is our breakthrough brachytherapy device. Unlike conventional external beam radiation therapy, OncoSil™ uses a targeted approach to deliver a calculated dose of radiation directly into the tumour. It enables doctors to target a greater radiation dose directly to the tumour, while sparing surrounding critical organs. OncoSil™ is intended for intra-tumoural implantation into a pancreatic tumour via injection under EUS guidance. The OncoSil™ device is intended to be used in conjunction with gemcitabine-based chemotherapy. iihttps://clinicaltrials.gov/ct2/show/NCT03003078 16.03.2021 Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World
NEW YORK, August 11, 2020 - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it is launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS). Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer, and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, lung, as well as others. In several multicenter, placebo-controlled trials in cancer patients with pain from bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo. Strontium89 is administered intravenously once every three months and for some patients can reduce or even eliminate the need for opioid analgesics; pain relief lasts from 2 - 5 months in most patients. Use of Strontium89 in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected, particularly in white blood cells and platelets. The extent of toxicity is variable but effects are generally transient. In randomized studies of Strontium89, the majority of hematologic toxicity was mild to moderate (Grade 2 or less) and white blood cell and platelet counts remained within approximately 70% of pretreatment levels. For more information including Important Safety Information please visit the Strontium89 page on Qbiomed.com. Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy, after manufacturing ceased in December of 2018. Q BioMed is pleased that the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population. In the meantime, Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in all major markets worldwide Denis Corin, CEO of Q BioMed, said of the program, “We are very happy that Strontium89 is once again available worldwide, and that physicians have the ability to prescribe a safe, effective and non-opioid treatment to their bone metastasis
pain patients regardless of their primary tumor type and notably beyond prostate cancer. We are actively working to ensure that Strontium89 is accessible to patients everywhere and to extend its relevance and use thorough additional
clinical study.” About Q BioMed Inc. Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the
strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need. About CCPS 03.12.2020 Helapet Updates Syringe/Endcap Integrity Testing for Compliant Preparation of Injectable MedicinesSyringe Caps & Pharmapack® Press release Helapet have announced that is has conducted new physical and microbiological integrity closure testing on their PharmaPack® range of sterile multi-pack BD syringes, in combination with a select range of syringe endcaps. The updated testing improves on existing compliances based on the recommended guidelines set down by the Pharmaceutical Aseptic Services Group (PASG) in their 2013 Yellow Document on the Protocols for the Integrity Testing of Syringes. Following the release of the 2013 Yellow Document it is now necessary for NHS Aseptic Production Units (APU’s) to assess the integrity of the applied syringe/endcap combinations when preparing injectable medicines. Using both microbiological and physical integrity testing, a comprehensive assessment of the luer-lock closure can be made and evidence used to approve the use of that syringe/endcap combination for the sterile preparation of patient medications. Two test methodologies were undertaken by a commissioned NHS Laboratory, involving a suitable number of test samples of syringe/endcap combinations subjected to microbiological and physical integrity testing. The microbial integrity evaluation involved sterile filling each sample, which was then challenged by immersion in a culture of Brevundimonas Diminuta and incubated at 30-35°C for 14 consecutive days. Physical integrity testing involved the samples being subjected to a dye intrusion test to determine whether any dye appeared to have entered the syringe barrel whilst under conditions matching those used for patient products. The results concluded that the selected syringe/endcap combinations demonstrated the suitable durability required to pass both integrity tests, delivering compliant syringe closure and secure protection against physical leakages and external microbial contamination. About Helapet Helapet has been a respected supplier to the NHS for over 30 years, supplying sterile single-use consumable products to meet the high standards and requirements of healthcare professionals working in aseptic working environments. Helapet is a member of the respected CliniMed® (Holdings) Group, comprising of eight specialist companies dedicated to supporting patient care through the supply of vital products into the healthcare industry. Further reading: https://www.helapet.co.uk/downloads/Integrity_Testing_of_Syringes_2013_2nd_Edn.pdf https://www.helapet.co.uk/downloads/29098_PharmaPack_Integrity_Testing_Summary_Datasheet.pdf
Contact: 07.04.2020 Curium Announces Approval of Pulmotech™ MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration(St. Louis, MO – March 24, 2020)- Curium announced today that the U.S. Food and Drug Administration (FDA) has approved Pulmotech MAA. When labeled to technetium Tc 99m, Pulmotech MAA is a single-photon emission agent for lung imaging as an adjunct in the evaluation of pulmonary perfusion and, in adults, to aid in the evaluation of peritoneovenous shunt patency. Curium has marketed a similar version of MAA (macroaggregated albumin) in Europe for more than a decade and expects to begin selling product to U.S. customers in April 2020. “We are excited to bring Pulmotech MAA to the market,” said Dan Brague, Curium CEO, North America. “Our customers have been asking us to expand our product portfolio to include an MAA product for several years. I am happy to share that we have listened and we are now able to help supply the needs of clinicians and their patients. This is the first in a series of anticipated approvals over the next two years in which Curium will bring solutions to the market.” “I am excited to bring a second MAA product to the U.S. market and look forward to engaging with customers on Pulmotech MAA immediately. This brand offers our customers significant value and is a tremendous addition to our growing portfolio of products in the U.S.” said Andy Farrow, VP of Sales, North America.
About Pulmotech MAA Curium offers customers the flexibility to purchase vials in either a pack of 5 or in a box of 30. To order any product in Curium’s portfolio, please contact Customer Service at 1-888-744-1414.
Indication Technetium Tc 99m Albumin Aggregated Injection is a radioactive diagnostic agent indicated for:
IMPORTANT RISK INFORMATION Contraindications
Warnings and Precautions
Adverse Reactions
Use In Specific Populations
Please see Full Prescribing Information at https://www.curiumpharma.com/pulmotech-maa
About Curium Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. To learn more, visit curiumpharma.com. For more information about this press release, please contact Janet Ryan media contact for Curium: janet@ryan-pr.com 24.03.2020 RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA(Houston, TX and St. Louis, MO – March 11, 2020) - RadioMedix Inc. and its commercial partner Curium announced the U.S. Food and Drug Administration (FDA) has granted copper Cu 64 dotatate injection a priority review. Copper Cu 64 dotatate is a PET diagnostic agent intended for somatostatin receptor (SSTR) expressing neuroendocrine tumors (NETs). Curium is preparing to launch copper Cu 64 dotatate in Q3 of this year. “If approved, we expect that copper Cu 64 dotatate injection will have a significant impact on physicians, neuroendocrine tumor patients and their caregivers as this will help alleviate the scheduling and supply challenges many geographies have experienced with other somatostatin analogue PET agents,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “We are preparing for the full-scale commercialization of copper Cu 64 dotatate injection and are excited to introduce a new product and a new isotope into the market. We are pleased that our significant efforts will result in helping neuroendocrine tumor patients receive a specific, sensitive and timely diagnosis,” said Curium CEO, North America, Dan Brague. About RadioMedix RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy. RadioMedix has research and contract service facilities for academic and industrial partners: the cGMP Dose Manufacturing and Analytical suites for the investigational clinical trials, and the Drug Discovery and Pre-clinical Core Facility for pre-clinical evaluation of drugs, both located in Houston, TX. Also, a second new state of art commercial manufacturing facility located in Humble, TX, has been recently established. To learn more, visit wwww.radiomedix.com. For more information about this press release, please contact:media@radiomedix.com. Follow us on social media: LinkedIn https://www.linkedin.com/company/radiomedix-inc-/ Facebook: https://www.facebook.com/RadioMedix-Inc/ About Curium Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. To learn more, visit curiumpharma.com. For more information about this press release, please contact Janet Ryan media contact for Curium:janet@ryan-pr.com. About Neuroendocrine Tumors Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as cervix, heart and prostate. Most NETs strongly express somatostatin receptors (SSTRs). 12.03.2020 Vent-Medis High Volume CrucibleXiel Ltd have been requested to cease all commercial activities with the Vent-Medis High Volume Crucible whist the MHRA legal team review if the product can be registered as both a pharmaceutical and medical device. Please see more details in the attached letter. As communicated in the attached letter and should you wish, we are offering to accept the return of all products sold since 19.11.19 for a full refund. Please confirm if this is an option you wish to explore and we will arrange collection of your Purchase order 200726889 at a convenient time, and issue a full credit against our invoice 253 dated 17.12.19. Please note that Xiel can continue to offer Servicing and Maintenance of Technegas Generators which are not impacted by the current MHRA request. Xiel ltd apologise for any inconvenience caused but can assure you we are working with the correct authorities to have this resolved as soon as possible and as soon as more information is received we will of course keep you updated. 23.01.2020 RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application(Houston, TX and St. Louis, MO – January 7, 2020) - RadioMedix Inc. and its commercial partner Curium announced today that the New Drug Application for copper Cu 64 dotatate injection was filed with the U.S. Food and Drug Administration (FDA). Copper Cu 64 dotatate injection is a PET diagnostic agent intended for somatostatin receptor (SSTR) expressing neuroendocrine tumors (NETs). The FDA previously granted Fast Track designation to copper Cu 64 dotatate injection. “If approved, we expect that copper Cu 64 dotatate injection will be the first FDA approved Cu 64 labeled radiopharmaceutical for PET/CT imaging. In addition, this drug will provide an exciting new imaging agent for NET physicians, patients and caregivers,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “Copper Cu 64 dotatate injection will be the first neuroendocrine PET diagnostic agent available to all medical centers with PET capability across the country. This will alleviate the scheduling and supply challenges many geographies have experienced with other somatostatin analogue PET agents. We are currently pursuing a Priority Review with the FDA to expedite commercial availability.” “If approved, the clinical utility of this new agent will allow Curium to enhance patient care in the U.S. by bringing the accuracy of PET SSTR to all hospitals and imaging centers,” said Curium CEO, North America, Dan Brague. “Our ability to manufacture copper Cu 64 dotatate injection at a central location and distribute quantities to meet the needs of hospitals and imaging centers demonstrates our continued focus on patients with neuroendocrine tumors. We are excited to be bringing Cu 64, an exciting new isotope for PET imaging, to the market. We look forward to exploring additional applications that can help patients and physicians.” About RadioMedix About Curium With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. To learn more, visit curiumpharma.com. For more information about this press release, please contact Janet Ryan media contact for Curium: janet@ryan-pr.com About Neuroendocrine Tumors 07.01.2020
Curium Acquires Finnish Radiopharmaceuticals Company
|
10/01/2025Wavelength - December 2024
10/01/2025Wavelength - November 2024
23/01/2025
Neuro Imaging Study Day
24/01/2025
Nuclear Medicine Careers
An interview with Gerard McKiernan for BNMS2024 https://youtu.be/sP4eRjS1Hb4?si=ZF1RPE5ge2qbu5do